Revance Therapeutics Inc represents values and a corporate philosophy focused on innovative medical solutions. The company is dedicated to developing and commercializing novel therapies for aesthetic and therapeutic indications. With their advanced proprietary technology, Revance aims to provide safe, effective, and long-lasting products to patients worldwide. By leveraging their expertise in neuromodulators and biotechnology, they strive to deliver groundbreaking treatments that meet the diverse needs of physicians and their patients. Revance Therapeutics Inc aims to establish itself as a trusted leader in the pharmaceutical industry through continuous research, development, and commitment to improving patient outcomes.

Revance Therapeutics Inc is primarily present in the United States.

Revance Therapeutics Inc has accomplished several significant milestones. One notable achievement is the development of DaxibotulinumtoxinA, their proprietary neuromodulator for aesthetic and therapeutic applications. The company also received approval for DaxibotulinumtoxinA by the United States Food and Drug Administration (FDA) for the treatment of glabellar lines in adults. Furthermore, Revance Therapeutics Inc successfully completed multiple clinical trials, demonstrating the safety and efficacy of their innovative products. These achievements highlight Revance Therapeutics Inc's commitment to groundbreaking research, development, and regulatory success in the field of neurotoxins.

Revance Therapeutics Inc is a renowned biotechnology company specializing in developing innovative cosmetic and therapeutic products. Established in 2002, Revance has emerged as a leader in advanced neuromodulator technology. With a strong focus on scientific research and clinical development, the company has successfully introduced breakthrough treatments for aesthetic and therapeutic purposes. Revance's proprietary drug delivery platform, known as TransMTS®, allows for precise and long-lasting results. Their notable achievements include FDA approval for DaxibotulinumtoxinA for Injection, a potent and next-generation Botox alternative. Revance Therapeutics Inc continues to revolutionize the industry, providing top-quality products and driving advancements in medical aesthetics.

The main competitors of Revance Therapeutics Inc in the market include Allergan plc, Johnson & Johnson, and Medytox Inc.

Revance Therapeutics Inc is primarily active in the healthcare and biotechnology industries.

Revance Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative aesthetic and therapeutic products. Their business model revolves around utilizing their proprietary peptide technology to develop next-generation neuromodulators and dermal fillers. By leveraging their expertise in drug delivery and using the power of botulinum toxins, Revance aims to provide long-lasting, reliable, and safe treatments for a wide range of medical and aesthetic conditions. Through a combination of rigorous research, clinical trials, and strategic partnerships, Revance Therapeutics Inc aims to revolutionize the field of aesthetics and offer novel solutions to patients worldwide.

P/E odnos Revance Therapeutics iznosi -2,50.

KUV kompanije Revance Therapeutics iznosi 1,97.

AlleAktien kvalitativni skor za Revance Therapeutics je 7/10.

očekivana Revance Therapeutics promet je 283,18 mil. USD.

Dobit očekivana Revance Therapeutics je -223,38 mil. USD.

Revance Therapeutics Inc. is a biopharmaceutical company that develops innovative technologies in collaboration with its business partners to revolutionize the healthcare market. The company was founded in 2002 and is headquartered in Newark, California. Revance Therapeutics specializes in the development of novel therapies for neurological, dermatological, and aesthetic indications. Revance Therapeutics has three different business segments: drug development, aesthetic medicine, and the sale of licensed technologies. Drug development: Revance Therapeutics has several drugs in the developmental phase for neurological and dermatological applications. One of these drugs is DaxibotulinumtoxinA, a botulinum toxin-like preparation developed for the treatment of uncontrolled saliva flow in patients with neurological disorders such as ALS (Amyotrophic Lateral Sclerosis) and MS (Multiple Sclerosis). Additionally, Revance Therapeutics is in advanced development for a topical product designed to treat chronically inflammatory skin diseases such as psoriasis and eczema. Aesthetic medicine: Revance Therapeutics operates an aesthetic medicine division that offers botulinum toxin preparations for aesthetic purposes such as reducing wrinkles and lifting the face. The company has developed a novel botulinum toxin preparation called DaxibotulinumtoxinA, which is in clinical trials for use in aesthetic medicine. The company also develops injectable fillers for aesthetic applications such as non-surgical nose correction. Licensed technologies: Revance Therapeutics offers its proprietary Aesthetic Delivery Platform technology (RTP technology) for sale to other companies. This technology allows for precise injection of botulinum toxin preparations and fillers into the skin, increasing the effectiveness and safety of injectable treatments and offering patients better results. Overall, Revance Therapeutics aims to develop first-class treatments for healthcare and beauty applications. The company is dedicated to conducting clinical trials to test the effectiveness and safety of its products. Over the years, Revance Therapeutics has received several investments from leading financial and institutional investors who recognize the company's potential to revolutionize the healthcare market. In the future, Revance Therapeutics plans to further expand its product range and develop innovative technologies to create a wider range of applications in healthcare and aesthetic medicine. The company strives to become the leading force in the field of botulinum toxin products and dermatological solutions.

Revance Therapeutics isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Revance Therapeutics trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Revance Therapeutics je US7613301099.

WKN od Revance Therapeutics je A1XD3D.

Oznaka za praćenje akcija kompanije Revance Therapeutics je RVNC.

U poslednjih 12 meseci, Revance Therapeutics je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Revance Therapeutics će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Revance Therapeutics trenutno iznosi .

Revance Therapeutics isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Revance Therapeutics je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Revance Therapeutics se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Revance Therapeutics od 24. 8. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 24. 8. 2024..

Isplata poslednje dividende izvršena je 24. 8. 2024..

U godini 2023 kompanija Revance Therapeutics je isplatila 0 USD kao dividende.

Dividende od Revance Therapeutics se isplaćuju u USD.